CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to OYST

OC-01 Low Dose, 0.12 mg/mL

Phase 3
Oyster Point Pharma, Inc. (OYST)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Long Term Follow up Dry Eye Disease

View Full Landscape
Drug Information

Target Indication

Long Term Follow up Dry Eye Disease

Clinical Trial

NCT03920215

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.